Gene therapy for macular degeneration: is it safe years later?
NCT ID NCT01678872
First seen Jun 27, 2026 · Last updated Jun 27, 2026
Summary
This study follows 18 people who already received RetinoStat, a gene therapy for wet age-related macular degeneration, to see if it remains safe over time. Researchers track side effects and vision changes. The goal is to understand long-term risks, not to test if the treatment works.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for AGE-RELATED MACULAR DEGENERATION are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
John Hopkins University Hospital
Baltimore, Maryland, 21287-9277, United States
-
Oregon Health & Science University
Portland, Oregon, 97239, United States
-
University of Iowa Hospitals & Clinics
Iowa City, Iowa, 52245, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- A sharper look at the retina: new imaging technology may spot eye disease earlier
- Eye injection aims to tame leading causes of blindness
- Higher-Dose eye injection may help wet AMD patients who Didn't respond to standard treatments
- Could light therapy help save sight in dry macular degeneration?
- Goji berry trial hopes to shield aging eyes from vision loss
- New eye drug aims to save sight in wet AMD